Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — Q3 FY26 Earnings Presentation
18 slides from Zim Laboratories's earnings presentation, Feb 11, 2026
Slide 1: Exchange filing cover letter for Q3 & 9MFY26 earnings presentation
Ref No.: ZLL/CS/BSE/NSE Date: 11.02.2026 BSE Limited, National Stock Exchange of India Limited Market Operations Dept. Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai – 400 051 Company Code- 541400 (Symbol - ZIMLAB) D
Slide 2: Zim Laboratories Limited Earnings Presentation Q3 & 9M FY26
ZIM LABORATORIES LIMITED E A R N IN G S P R E S E N TATIO N Q3 & 9M FY26 www.zimlab.in
Slide 3: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 4: Content
CONTENT 01 Q3 & 9MFY26 - HIGHLIGHTS 02 FINANCIAL PERFORMANCE Q3FY26 03 BUSINESS MIX 04 R&D & INNOVATION 05 SHAREHOLDING 3
Slide 5: Q3 & 9MFY26 Highlights
Q3 & 9MFY26 HIGHLIGHTS Financial Highlights (9MFY26) Financial Highlights (Q3FY26) Total Operating Income at ₹2,691 Total Operating Income reached ₹1,087 Mn, declined by 0.4% in 9MFY26 vs Mn in Q3FY26, reflecting a 12.8% ₹2,703 Mn in 9MFY25. growth vs ₹ 963 Mn in Q3FY25. EBITDA is at ₹280 Mn, declin
Slide 6: Investment Plan
INVESTMENT PLAN Star Product 2 – Dedicated facility planned to cater to business opportunities primarily for EU/UK/Developed Markets To be Utilised for The Board has approved, subject to shareholder and regulatory approvals, the issuance of up to 47,64,497 Standalone Nutraceutical facility equity sh
Slide 7: Status Update and Progress on CAPA Remediation
STATUS UPDATE AND PROGRESS ON CAPA REMEDIATION The company has completed and implemented most of it CAPA remediation plan and will be ready for inspection from March 2026 onwards Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY26 June / July EU GMP Inspection Submission of CAPA Progress Submission of CAPA Progress Reg
Slide 8: Financial Performance – Q3FY26
FINANCIAL PERFORMANCE – Q3FY26 Total Operating Income EBITDA & EBITDA margin Profit After Tax (PAT) & PAT margin 7.9% 8.8 % 13.4% -2.6 % -0.5 % 4.0 % 1,087 44 145 887 718 78 57 -4 Q1FY26 Q2FY26 Q3FY26 -19 Q1FY26 Q2FY26 Q3FY26 Q1FY26 Q2FY26 Q3FY26 o Total Operating Income at ₹1087 Mn, reflecting a 22
Slide 9: Business Mix
BUSINESS MIX Pharma Revenue (₹ Mn) & Contribution to Total Nutra Revenue (₹ Mn) & Contribution to Total Operating Income (%) Operating Income (%) 82% 83% 33% 77% 78% 71% 72% 29% 28% 67% 23% 22% 18% 17% 300 891 266 268 739 732 786 224 654 196 552 560 158 155 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26
Slide 10: Revenue Mix
REVENUE MIX 39, 4% 17, 2% 98, 4% 336, 13% 109, 10% 144, 15% 358, 13% 65, 2% Q3FY25 Q3FY26 9MFY25 9MFY26 780, 81% 2,247, 83% 2,290, 85% 961, 88% Export India Deemed Export Export India Deemed Export Export India Deemed Export Export India Deemed Export Numbers in ₹Mn o Q3FY26: Export business share i
Slide 11: Innovative Product Contribution
INNOVATIVE PRODUCT CONTRIBUTION (NIP + OTF) Revenue (₹ Mn) & Contribution to Total Operating Income (%) 21.8% 17.8% 14.0% 13.5% 12.2% 12.7% 9.2% 178 164 9.5% 147 8.5% 135 6.3% 132 109 112 82 81 46 Q2 FY 24 Q3 FY 24 Q4 FY 24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3FY26 o Q3FY26: NIP + OTF o
Slide 12: Advancing Innovation: NIP Product Pipeline (EU/UK)
ADVANCING INNOVATION : NIP PRODUCT PIPELINE (EU/UK) Formulation Regulatory Regulatory Commercial Product Therapy Area Market Review Validation BE Studies Development Filing Approvals Supplies Product 1 Urology Product 2 Gastrointestinal Product 3 Anti – Coagulant Di-Methyl Fumarate CNS Product 5 Uro
Slide 13: Advancing Innovation: OTF Product Pipeline (EU/UK)
ADVANCING INNOVATION : OTF PRODUCT PIPELINE (EU/UK) Formulation Regulatory Regulatory Commercial Product Therapy Area Market Review Validation BE Studies Development Filing Approvals Supplies Rizatriptan CNS Sildenafil Erectile Dysfunction Product 3 CNS Product 4 Erectile Dysfunction Buprenorphine O
Slide 14: R&D Driving Product Innovation
R&D DRIVING PRODUCT INNOVATION R&D Expense Mix % of Total R&D Investment and Total R&D Investment as % of Total Operating Income 96 2 80 9.7% 8.6% Capital Expenses on BE study, 33% 33% registrations etc R&D Team Post- PhDs Size Graduates 3% 1% Capital Expenses on Infrastructure & Equipment 7 4 ₹230
Slide 15: Strengthening Leadership and Organizational Capabilities
STRENGTHENING LEADERSHIP AND ORGANIZATIONAL CAPABILITIES Senior Management strengthened over the last 9 months (9MFY26) Mr. Vikrant Bendre Mr. Sridhar Reddy R Mr. Jitendra Pandey Srinivas Chowdary President, International Business VP, Quality Assurance (SMP) VP, Human Resources (SMP) VP, Purchase •
Slide 16: Income Statement
INCOME STATEMENT Particulars (₹ Mn) Q3FY26 Q3FY25 YoY% 9MFY26 9MFY25 YoY% Total Operating Income 1,087 963 12.8% 2,691 2,703 -0.4% Other Income 17 18 -5.4% 52 41 27.3% Total Income 1,104 981 12.5% 2,743 2,744 0.0% EBITDA 145 133 9.1% 280 332 -15.5% EBITDA % 13.4% 13.8% (46) bps 10.4% 12.3% (186) Bps
Slide 17: Shareholding
SHAREHOLDING Ownership % (December 2025) Traded Volume (In K) BSE+NSE 5% 26,593 33% 18,435 16,660 43% 14,093 14,104 11,313 11,016 5,734 12% 7% Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Promoter HNI Body Corporates Other Public Shareholding • Number of Shareholders as on Dec 2025 accoun
Slide 18: Investor Relations Company Contact
Investor Relations Company Contact Mr. Zain Daud Ms. Sheetal Khanduja Address Zim Laboratories Limited Go India Advisors Sadoday Gyan (Ground Floor), Opposite NADT, Nelson Square, zain.daud@zimlab.in sheetal@GoIndiaAdvisors.com Nagpur, Maharashtra 440013 M:+91 9022434631 M:+91 97693 64166 www.zimlab